140 related articles for article (PubMed ID: 38903035)
1. [Not Available].
Todorovac N; Hansen MS; Elpert FP
Ugeskr Laeger; 2024 Jun; 186(24):. PubMed ID: 38903035
[TBL] [Abstract][Full Text] [Related]
2. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
Doggrell SA
Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
[TBL] [Abstract][Full Text] [Related]
3. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
4. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
5. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
6. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P
Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Davidson M
Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
[TBL] [Abstract][Full Text] [Related]
8. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
Miltiadous G; Saougos V; Cariolou M; Elisaf MS
Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
[TBL] [Abstract][Full Text] [Related]
9. Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia.
Ferrari F; Martins VM; Rocha VZ; Santos RD
Expert Opin Pharmacother; 2021 Mar; 22(4):483-495. PubMed ID: 33016816
[TBL] [Abstract][Full Text] [Related]
10. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
11. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
13. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
[TBL] [Abstract][Full Text] [Related]
14. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
16. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
[TBL] [Abstract][Full Text] [Related]
17. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
Olsson AG; Nilsson PM
Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
[No Abstract] [Full Text] [Related]
18. Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting.
Scicali R; Di Pino A; Ferrara V; Rabuazzo AM; Purrello F; Piro S
Acta Diabetol; 2021 Jul; 58(7):949-957. PubMed ID: 33745063
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Review of PCSK9 Inhibitors.
Coppinger C; Movahed MR; Azemawah V; Peyton L; Gregory J; Hashemzadeh M
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221100107. PubMed ID: 35593194
[TBL] [Abstract][Full Text] [Related]
20. Familial hypercholesterolemia: current treatment and advances in management.
Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
